Immutep Showcases Innovative Cancer Immunotherapy Research

Immutep's Pivotal Presentation at the European Lung Cancer Congress

SYDNEY, AUSTRALIA — Immutep Limited (ASX: IMM; NASDAQ: IMMP), a prominent late-stage immunotherapy company focused on treating cancer and autoimmune diseases, has announced an exciting opportunity at the upcoming European Lung Cancer Congress (ELCC). The congress, taking place in Paris, promises to be a significant event for medical professionals in the field of lung cancer.

The company will showcase a poster presentation focusing on the pivotal TACTI-004 Phase III trial. This presentation will occur during the congress scheduled from March 26 to March 29. Attendees hungry for knowledge will gain insights into the innovative study and its implications for future lung cancer treatments.

Overview of the TACTI-004 Phase III Trial

The TACTI-004 trial is designed to investigate the effects of Immutep's MHC Class II agonist, eftilagimod alfa (efti), in combination with MSD's (Merck & Co., Inc.) anti-PD-1 therapy, KEYTRUDA (pembrolizumab), and chemotherapy. This promising regimen is aimed at patients facing advanced or metastatic non-small cell lung cancer (1L NSCLC).

Approximately 750 patients from various backgrounds will be enrolled, incorporating diverse PD-L1 expression profiles and tumor types. This global trial will be conducted across over 150 clinical sites in more than 25 countries, showcasing the commitment to understanding and improving treatment outcomes on an international scale.

Engaging with the Oncology Community

Frédéric Triebel, Immutep's Chief Scientific Officer, expressed enthusiasm about engaging with the lung cancer community at the ELCC. He emphasized the potential of combining efti with KEYTRUDA to revolutionize treatment approaches for patients. Triebel highlighted the trial's ongoing recruitment efforts and optimism that the results will support the promising safety and efficacy profiles observed so far.

Details of the Poster Presentation

For those attending the ELCC, the details of the poster presentation are as follows:

• Title: TACTI-004: a double-blinded, randomized phase 3 trial in patients with advanced/metastatic non-small cell cancer receiving eftilagimod alfa (MHC class II agonist) in combination with pembrolizumab (P) and chemotherapy (C) versus placebo + P + C
• Presentation Number: 131TiP
• Presenter: Margarita Majem, MD, PhD, Hospital de la Santa Creu i Sant Pau
• Session Date and Time: March 26, 2025, at 13:50 CET

After the presentation, the poster will also be accessible on Immutep's website, providing a resource for further insight into the trial.

About Eftilagimod Alfa

Eftilagimod alfa is a groundbreaking immunotherapy developed by Immutep, designed to stimulate both innate and adaptive immunity against cancer. As a first-in-class antigen presenting cell (APC) activator, efti significantly enhances the immune system's capacity to combat malignancies. It achieves this by activating critical immune cells, including CD8+ cytotoxic T cells and CD4+ helper T cells.

The Future of Efti in Cancer Treatment

Currently, efti is under extensive evaluation for several solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, and metastatic breast cancer. Its remarkable safety profile allows incorporation with various treatment regimens, particularly anti-PD-[L]1 immunotherapy and chemotherapy. Notably, efti has received Fast Track designation from the FDA for first-line treatment in both HNSCC and NSCLC.

About Immutep

As a pioneer in advancing immunotherapy solutions, Immutep is dedicated to harnessing the power of Lymphocyte Activation Gene-3 (LAG-3) for therapeutic purposes. Their robust product portfolio is focused on enhancing the immune response for the benefit of patients, while consistently striving to deliver innovative treatment options and maximizing shareholder value.

For more in-depth information about Immutep and its initiatives, visit their official website.

Frequently Asked Questions

What is the TACTI-004 trial about?

The TACTI-004 trial aims to evaluate the efficacy of eftilagimod alfa combined with KEYTRUDA and chemotherapy for treating advanced non-small cell lung cancer.

When will the poster presentation take place?

The presentation is scheduled for March 26, 2025, at 13:50 CET during the European Lung Cancer Congress in Paris.

How many patients will be enrolled in the TACTI-004 trial?

Approximately 750 patients will participate in the global trial, regardless of their PD-L1 expression and tumor type.

What is efti and its role in immunotherapy?

Efti is an MHC Class II agonist that enhances the immune system's ability to fight cancer by activating critical immune cells.

What other cancers are being explored for treatment with efti?

Efti is currently being evaluated for non-small cell lung cancer, head and neck squamous cell carcinoma, and metastatic breast cancer, among others.

About The Author

Hi there, As a writer and financial specialist, Henry Turner is passionate about guiding people through the complex world of finance. Having worked in finance for many years, I am an expert at simplifying difficult financial ideas into understandable, useful insights for my blog and articles. My goal is to arm you with the confidence and information you need to make wise financial choices.

Writing for a number of financial blogs has allowed me to interact with readers from novice investors looking for fresh ideas to seasoned investors starting their financial journeys. My mission is to enable everyone to understand and access finance, so enabling you to confidently and clearly reach your financial goals. I appreciate you traveling with me toward success and financial literacy.

Contact Henry Turner privately here. Or send an email with ATTN: Henry Turner as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.